Valuation: Nipro Corporation

Market Cap 26TCr 155.84Cr 137.06Cr 127.33Cr 117.11Cr 219.62Cr 15TCr 223.55Cr 1.52TCr 593.89Cr 7.36TCr 585.05Cr 572.4Cr P/E 2027 *
17.5x
P/E 2028 * 12.9x
Enterprise Value 77TCr 467.56Cr 411.22Cr 382.02Cr 351.36Cr 658.91Cr 45TCr 670.72Cr 4.57TCr 1.78TCr 22TCr 1.76TCr 1.72TCr EV / Sales 2027 *
1.09x
EV / Sales 2028 * 1.02x
Free-Float
87.38%
Yield 2027 *
2.2%
Yield 2028 * 2.94%
14/07 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
12/05 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
12/05 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
01/05 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
11/03 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
09/02 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
24/12 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
10/11 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/25/10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/25/09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/25/13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
12/25/12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
12/25/12 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
1 day+1.38%
1 week-0.32%
Current month-0.10%
1 month-2.60%
3 months+2.61%
6 months+8.47%
Current year+6.64%
1 week 1,544
Extreme 1544
1,613.5
1 month 1,531
Extreme 1531
1,648.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,353
Extreme 1353
1,760.5
3 years 1,015.5
Extreme 1015.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
President 58 26/06/2025
Chief Administrative Officer 57 26/06/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 57 01/06/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%-0.32%+16.62%+51.37% 160.3Cr
+0.18%+1.94%-19.93%-11.85% 18TCr
+0.15%-1.85%-10.87%-7.81% 10TCr
+1.49%-0.95%+3.96%+58.40% 5.85TCr
-1.37%-1.92%+32.17%+54.82% 5.14TCr
-0.12%-4.35%-16.22%-42.24% 4.22TCr
+1.21%-8.47% - - 3.14TCr
-1.33%-9.62%-18.45%-46.03% 2.76TCr
-0.82%-1.92%+56.39%-5.79% 2.53TCr
+0.03%-4.74%-6.58%-9.24% 2.05TCr
Average +0.13%-2.72%+4.12%+4.62% 5.38TCr
Weighted average by Cap. +0.17%-1.21%-5.17%+0.06%

Financials

2027 *2028 *
Net sales 70TCr 427.2Cr 375.72Cr 349.04Cr 321.02Cr 602.02Cr 41TCr 612.82Cr 4.17TCr 1.63TCr 20TCr 1.6TCr 1.57TCr 73TCr 444.8Cr 391.2Cr 363.42Cr 334.25Cr 626.82Cr 43TCr 638.06Cr 4.35TCr 1.7TCr 21TCr 1.67TCr 1.63TCr
Net income 1.48TCr 9.02Cr 7.93Cr 7.37Cr 6.78Cr 13Cr 873.46Cr 13Cr 88Cr 34Cr 426.04Cr 34Cr 33Cr 2TCr 12Cr 11Cr 9.96Cr 9.16Cr 17Cr 1.18TCr 17Cr 119.05Cr 46Cr 575.57Cr 46Cr 45Cr
Net Debt 51TCr 311.72Cr 274.16Cr 254.69Cr 234.25Cr 439.3Cr 30TCr 447.17Cr 3.05TCr 1.19TCr 15TCr 1.17TCr 1.14TCr 49TCr 299.95Cr 263.8Cr 245.07Cr 225.4Cr 422.69Cr 29TCr 430.27Cr 2.93TCr 1.14TCr 14TCr 1.13TCr 1.1TCr
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
24/26/24 JP¥1,576.00 +1.45% 1,11,000
23/26/23 JP¥1,553.50 -2.33% 7,31,700
22/26/22 JP¥1,590.50 -0.53% 3,50,500
21/26/21 JP¥1,599.00 +0.44% 5,24,300
17/26/17 JP¥1,592.00 +0.76% 5,72,800
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,553.50JPY
Average target price
1,982.00JPY
Spread / Average Target
+27.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock